Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $6
Ascendiant Capital analyst Edward Woo maintains IGC Pharma (AMEX:IGC) with a Buy and raises the price target from $5.5 to $6.
Read original at benzingaStocks · News reference
IGC Pharma Q2 EPS $(0.03) Misses $(0.02) Estimate, Sales $265.000K Beat $258.000K Estimate
IGC Pharma (AMEX:IGC) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is a 50 percent decrease over losses of $(0.02) per share from the same
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 17, 2026, 12:40 PM
- Checked
- Aug 17, 2026, 12:40 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
IGC Pharma Says Phase 2 CALMA Trial Of IGC-AD1 In Alzheimer's Agitation Has Randomized 160 Participants To Date, With Topline Results Expected In Q4 2026
Read original at benzinga'THC And CBD From Marijuana Reduces Agitation In 9 Out Of 10 People With Alzheimer’s Or Other Dementia, Study Shows' - Marijuana Moment
https://www.marijuanamoment.net/thc-and-cbd-from-marijuana-reduces-agitation-in-9-out-of-10-people-with-alzheimers-or-other-dementia-study-shows/
Read original at benzinga